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1. Introduction 
Here we will review the somewhat surprising, and novel emerging use of the classic model 
organism Dictyostelium discoideum, a species of soil-living amoeba, as a valuable biomedical 
tool to study the function of mutant genes implicated in human neurological disorders. 
Many neurodegenerative disorders, although related by their destruction of brain function, 
display remarkable cellular and/or regional pathogenic specificity most likely initiated 
through some deregulated aspect of the activity of the mutant protein. However, the 
expression of many neurodegenerative disease genes, including but not limited to huntingtin 
(HTT), the ataxins, the presenilins (PSEN1/PSEN2) are not simply localized to neurons but are 
found ubiquitously expressed throughout peripheral tissues. It is safe to say that when 
considering neurodegeneration, a term used to describe the progressive loss of function or 
death of neurons; it is paramount to properly understand the earliest precipitating events 
that lead to neuronal pathogenesis in order to ultimately develop long-term effective 
therapies. This means, in no unequivocal terms, that it is critical to understand the normal 
function of the disease-causing gene. Unfortunately, the normal function(s) of a large 
majority of mutant genes remain largely unknown which may in fact delay, and often 
precludes the development of assays for rapid and accurate assessment as to how the 
mutation initiates disease. As a result, a variety of lower and higher metazoan model 
systems have been established that range from worms to flies to mice, all designed to better 
understand neurological disease in humans. So the question arises: how reasonable is the 
use of simple organisms to study neurological disorders especially when the model of 
choice does not contain neurons? Historically, I believe the evidence suggesting the 
usefulness of using simple organisms to understand the etiology of cellular pathology 
cannot be denied. But using an organism without a central nervous system to understand 
diseases of the brain? The intrinsic complexity of the brain, without question, greatly 
complicates the accessibility to study the biochemical processes that contribute to pathology. 
Furthermore, functional genomic studies through the targeted deletion of genes may 
preclude their study due to essential cellular roles. As a consequence, determining the direct 
functional role and subsequent alteration of function by the mutation through phenotypic 
analysis is once again complicated further. Specifically, this has been true for huntingtin, the 
causative agent of Huntington’s disease, and the beta-amyloid precursor protein (APP) and 
presenilins, responsible for the onset of Alzheimer’s disease (AD) as well as a host of other 
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neurological disorders where candidate mutant genes have been discovered but cannot 
readily be assigned a function. Reverse genetics in mice, the “gold standard” in human 
disease models, have shown that a number of disease genes including those mentioned 
previously are critical components involved in embryonic developmental. So again, the 
question might arise why Dictyostelium? The haploid life cycle of Dictyostelium is fascinating 
from a biological perspective, and provides unique opportunities to assess disease-related 
questions because it can be studied naturally as both single, dynamic independent cells and 
as a bona fide multicellular organism in a highly meaningful way with exceptional cellular 
clarity. Second, and importantly, unlike metazoans, growth precedes development in this 
eukaryotic organism. As such, targeted deletions of homologous disease genes that do not 
affect growth can be readily studied in great biochemical detail when the cells are induced 
to proceed through development with unparalleled synchronous timing and a robustly 
consistent pattern of gene expression even across evolutionarily divergent species (Parikh et 
al. 2010). Finally, since the completion of the Dictyostelium genome project a number of 
reviews on the use of this model system to elucidate mechanisms of disease including actin 
pathologies, mitochondrial disease, human lysosomal and trafficking disorders, host-
pathogen interactions and anti-cancer drug action have been described (Carnell & Insall, 
2011; Clark, 2010; Francione et al. 2011; Maniak, 2010; R.S. Williams et al. 2006). As will be 
reviewed below, the evolutionary conservation between Dictyostelium and human genes 
implicated in neurodegeneration, combined with the organisms genetic tractability and easy 
cellular accessibility, it can be argued that this model system, along side many other human 
diseases, also provides a fertile environment for discovering normal gene function(s) that 
cause neurodegeneration with the significant potential for translational and validation 
studies in higher eukaryotes including both mouse and human systems. 
2. Contributions of Dictyostelium to neurodegenerative disease-gene 
function 
When readers of this chapter pause to think about Dictyostelium, if at all, at least not since 
their Introductory Biology course back in University, I have a hunch that they might 
recollect faint memories of laboratory demonstrations involving cAMP-mediated 
chemotaxis or the observation of various developmental structures including fruiting bodies 
made up of spores and stalks that form from starved individual amoebae. Whereas bacteria, 
yeasts and several other invertebrate or vertebrate model systems are well known for their 
additions to our understanding of basic biology and human disease, Dictyostelium, 
unfortunately is rarely included among this list. However, quietly, over the last few years, 
primarily following the publication of the genome, public availability of RNA seq data and 
DNA microarray data, research conducted on the social amoeba has revealed some very 
common cellular features shared across various phyla, and almost uncannily, that many of 
its proteins are more similar to human orthologues than are those of S. cerevisiae (Eichinger 
et al. 2005). Moreover, unlike yeasts, the 34 Mb, Dictyostelium genome is densely populated 
with 12,646 genes and is surprisingly close in size to the 13,676 genes found in the Drosophila 
genome (Adams et al. 2000). I wish to suggest that, despite the wide evolutionary distance 
that separates humans and the social amoeba, mutations in Dictyostelium can provide direct 
insight into human neurological disease processes. In this chapter I will discuss in detail 
research using this organism on genes known to cause neurodegenerative disorders 
including Alzheimer’s disease, Huntington’s disease and Hirano bodies. However, 
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Dictyostelium also contain many other genes related to neurological disease including, but 
not limited to Adrenoleukodystrophy (ABCD1), Amyotrophic lateral sclerosis (SOD1), 
Miller-Dieker Lissencephaly (LIS1), Parkinson’s disease (UCHL1) and Neuronal ceroid 
lipofuscinosis (PPT1, CLN2, CLN3, CLN5) (Eichinger et al. 2005). Later in this chapter I will 
introduce an emerging role for Dictyostelium in pharmacogenetics. More specifically, 
discoveries in Dictyostelium on the effects of valproic acid have uncovered common modes 
of action in mammalian neurons (R.S. Williams, 2005). Lastly, I will describe in detail in vitro 
studies using the unique small molecule DIF-1 (differentiation-inducing factor-1; 1-(3, 5-
dichloro-2, 6-dihydroxy-4-methoxyphenyl) hexan-1-one), a morphogen produced by 
Dictyostelium, that has been shown to have anti-amyloid properties in a wide variety of 
mammalian cell types (Myre et al. 2009). DIF-1 selectively reduces the amyloidogenic 
processing of wild type and mutant APP (e.g., early onset mutations) which dramatically 
prevents production of Abeta40 and Abeta42, believed to be the causative agent of AD. 
Alzheimer’s disease, the most common form of dementia among older adults, is 
nonreversible, and with the number of AD cases on the rise in the absence of effective 
treatments, it becomes even more urgent to explore and identify molecules with potential 
therapeutic potential. In essence, as a research community, what I hope to convince you of is 
that it is important we “leave no stone unturned”. 
2.1 Dictyostelium – Emergence of a classic model organism for the study of human 
disease 
Dictyostelium discoideum is a species of soil-living amoeba belonging to the Kingdom 
Amoebozoa and phylum Mycetozoa. Dictyostelium, now commonly referred to as social 
amoeba, is a eukaryote that transitions from a collection of individual, self-sustainable 
phagocytic amoebae into a multicellular slug and then into a fruiting body within its life 
cycle (Figure 1a).  
Upon starvation conditions, Dictyostelium transitions from a unicellular to a bona fide 
multicellular organism. During this period of multicellular development, the cells execute a 
series of morphological changes that proceed in defined stages over a 24 hour period. 
Within the first six hours of development, cells secrete, and undergo chemotaxis toward 
cyclic adenosine monophosphate (cAMP) to form aggregation territories. The secretion of 
cAMP promotes a G protein-coupled receptor signaling cascade that results in the formation 
of discrete mounds that may contain as many as 100,000 cells (Parent & Devreotes, 1996; 
Soderbom & Loomis, 1998). As development continues, cells within the mound remain 
motile and are directed to differentiate into either prestalk or prespore cells, leading to 
morphogenetic changes yielding a multicellular stalk, supporting a ball of encapsulated 
dormant spores (J.G. Williams et al. 1989). The entire process showing the various 
developmental structures is beautifully depicted in Figure 1b by scanning electron 
microscopy (SEM) and although the description of the life cycle appears simplistic, the 
process in actuality is quite complex with still many unresolved questions including the 
transition from growth to development, on how cells secrete cAMP, regulate organism size, 
and initiate cell-fate choices to name but a few. A PubMed search of the term Dictyostelium 
retrieves well over 7,000 articles with more than 600 reviews available to the reader that 
explore the life cycle in much greater detail than is presented here. It is now quite clear that 
Dictyostelium possesses signal-transduction pathways that are closely related to those of 
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metazoa. Yet, with at least one major and exploitable fundamental difference: animals 
undergo embryogenesis, that is to say they develop from a single cell by a combination of 
cell division, morphogenetic movements and differentiation followed by growth of the 
organism. Whereas with Dictyostelium, growth precedes development, and in contrast, 
development requires no growth, and multicellularity is achieved by the concerted 
aggregation of many unicellular amoebae. This greatly simplifies the study of development 
and provides an exceptionally easier route to examine numerous cellular functions 
including cytokinesis, endocytosis, secretory pathways, protein trafficking, intracellular 
signaling, gene transcription and regulation, cell-cell communication and adhesion, 
differentiation and many molecular and biochemical aspects of random and directed cell 
motility. In addition, Dictyostelium cells undergo a relatively simple program of 
multicellular development, which in many ways resembles animal development. With the 
sequencing of the genome we are now entering a renaissance in the use of this model 
organism as a biomedical research tool.  
 
Fig. 1. The life cycle of Dictyostelium discoideum. (A) Most of its life exists in its growth phase, 
as a haploid social amoeba preying upon bacteria in the soil and dividing by mitosis. Once 
the food source is depleted cells enter into a 24 hour multicellular developmental program. 
During this transition, amoebae aggregate towards secreted cAMP by chemotaxis in the 
thousands to form a tight mound and then enter a stage where cells begin to differentiate. 
Cells within the mound remain motile and are directed to differentiate, by secreted 
morphogens, into either prestalk or prespore cells, culminating to form a fruiting body 
comprised of a multicellular stalk that supports a ball of encapsulated dormant spores. (B) 
Scanning electron microscopy showing the various structures formed during development. 
Permissions: CC Creative Commons Attribution - Share Alike 3.0, David Brown & Joan E. 
Strassmann. SEM courtesy of MJ Grimson & RL Blanton, Biological Sciences Electron 
Microscopy, Texas Tech University. 
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As will be discussed in more detail later, Dictyostelium offers numerous advantages as an 
experimental organism. Its haploid genome is gene dense, and where higher eukaryotes 
may express a large number of similar genes with redundant functions, Dictyostelium often 
carries only a single homologous or orthologous gene. In addition, GFP-fusions, expressed 
sequence tags, RNAi and just about all molecular biochemical experimentation can be 
performed using the organism with exceptional cellular clarity between differentiated cell 
types. Most importantly, genetic manipulation of Dictyostelium by targeted gene deletion 
using homologous recombination can be performed relatively quick and for a fraction of the 
cost of higher eukaryotic systems. In order to unveil the functions of homologous proteins 
by studying them in simple model systems, it is important that these functions retain a 
respectable level of conservation through the course of evolution. In many cases, it is 
possible to demonstrate directly, the conservation of function(s) of homologous proteins 
among species by expressing a recombinant version of the protein in a null genetic 
background and showing the restoration of phenotypic deficiencies. Importantly, to suggest 
the use of Dictyostelium as a model system to understand the normal function of human 
neurological disease genes, when the difficulty of using more complex eukaryotic models 
have either failed or provided only limited indirect information, there must, at the very least 
be a significant level of homology present. Sequencing of the Dictyostelium genome revealed 
that many genes encode proteins that meet this criterion of homology to their mammalian 
counterparts, and some have been shown to be extremely conserved throughout evolution 
at the amino acid level (>70%) (e.g., calmodulin has 88% identity, actin has 94% identity; see 
www. http://dictybase.org) and, are also functionally equivalent in an experimental setting. 
In Dictyostelium, some proteins that retain functional equivalence include but are not limited 
to Vmp1, a vacuolar membrane protein, involved in vesicle trafficking, autophagy, growth 
and morphogenesis in mammals but not yeast; Rbl1, retinoblastoma-like protein, which 
causes loss of retina structure/architecture, and ABP34, an actin-bundling protein that 
causes the formation of Hirano bodies in mammalian neurons (reviewed in Annesley & 
Fisher, 2009). Moreover, the sequencing of the Dictyostelium genome revealed, at a highly 
conservative and stringent threshold value of e ≤ 10-40, the presence of at least 64 proteins 
involved in a variety of human diseases that were similar in size and amino acid identity 
extending over 70% of the protein (Eichinger, et al. 2005). However, at this level of 
stringency, the number of orthologous Dictyostelium proteins involved in human diseases 
(e.g., PSEN1, PSEN2, HTT, Neurofibromatosis 1, LRRK2) are not as readily recognized, and 
so the actual number of predicted human disease proteins present in the genome is very 
likely to be much higher (Bosgraaf & Van Haastert, 2003; McMains et al. 2010; Myre et al. 
2011; S. Zhang et al. 2008). Future biomedical research using this organism will undoubtedly 
continue to illuminate many more human disease genes with conserved function. Finally 
another strength that supports the use of this model are the multiple facets of the life cycle, 
where it can be observed at the organismal, cellular, biochemical and molecular level, all in 
the same system and with an extremely limited degree of artifact that is far more common 
among mammalian cell culture. This includes the issues of biological contamination of 
mammalian cell culture; between 11 percent and 15 percent of cultures in U.S laboratories 
have been or are infected with species of Mycoplasma (Lincoln & Gabridge, 1998), which 
affect the host cells’ metabolism, morphology, cause chromosomal damage, and can 
provoke cytopathic responses, rendering any data from contaminated cultures unreliable. 
There are no reports that I am aware of detailing infection of Dictyostelium cultures with 
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Mycoplasma, or, surprisingly, no large DNA virus that infects Dictyostelium have been 
detected thus far. Taken together, the simplicity of its life cycle makes Dictyostelium a 
valuable model organism to study conserved genetic, cellular, and biochemical processes 
with a very high degree of translation in other model organisms from flies to zebrafish. 
2.2 Alzheimer’s disease 
Dementia is an acquired condition typified by a severe decline in memory and other 
cognitive abilities. It represents a recession from an individuals established level of 
intellectual capacity that sufficiently interferes with their everyday ability to function. 
Alzheimer’s disease (AD) is the most common cause of dementia, estimated to contribute to 
about 60 to 70% of cases (Barker et al. 2002). Estimates suggest that ~ 5.3 million Americans 
are afflicted with AD (http://www.alz.org), or ~1 in 8 people older than 65, with an 
estimated worldwide prevalence of AD approaching 30 million people and a quadrupling of 
numbers expected to occur over the next 40 years. The time course of AD averages 7 to 10 
years, characterized by loss of specific neuronal populations and synapses in the cerebral 
cortex and certain subcortical regions that culminates in extreme atrophy of the diseased 
regions, including degeneration in the temporal lobe, parietal lobe, and parts of the frontal 
cortex and cingulate gyrus (Wenk, 2003). AD is a terminal disease that culminates in death. 
Impaired recent memory usually is an initial symptom of AD, but other cognitive deficits 
(e.g., changes in attention, problem-solving abilities) may also be present. Amyloid plaques 
and neurofibrillary tangles (NFTs), the characteristic pathological hallmarks of AD, are 
believed to be causative and accrue in the years preceding clinical symptoms. 
2.2.1 The amyloid precursor protein and discovery of presenilin-dependent  
gamma-secretase activity 
Amyloid plaques are accumulations of insoluble protein aggregates in the extracellular 
space of the brain. The principal proteinaceous component of plaques is the Abeta peptide, a 
38– to 43–amino acid peptide derived from a much larger pre-cursor protein, the amyloid 
precursor protein (APP) (Golde et al. 2000; Hardy & Selkoe, 2002). APP is a type I integral 
membrane protein with a single-pass C-terminal transmembrane domain. Several isoforms 
of APP have been identified, the most common being comprised of 695, 751, or 770 amino 
acids, are highly expressed in the central nervous system and particularly enriched in 
neurons. Abeta peptides are derived from APP through the sequential enzymatic activity of 
two proteases, beta-secretase (BACE) and gamma-secretase, respectively. In addition to 
Abeta, these cleavage events also liberate an APP intracellular fragment (AICD) that has 
been suggested to have a transcriptional function (Cao & Sudhof, 2001). APP was identified 
as the first gene in which mutations in the coding sequence cause early-onset familial 
Alzheimer’s disease (FAD) (Goate et al. 1991; Levy et al. 1990). The identification and 
location of mutations within the APP gene have provided important clues regarding the 
potential pathological mechanisms that lead to increased Abeta production in the brain in 
FAD, but have not been as insightful in the pathology of late-onset AD in which individuals 
do not contain mutant APP. The normal function of APP is not well understood. However, a 
review on the function and proteolytic processing of APP is beyond the scope of this chapter 
and can be thoroughly reviewed elsewhere (Y.W. Zhang et al. 2011).  
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In addition to APP, mutations in two other genes have been identified that when mutated 
result in the rare, autosomal dominant forms of early-onset FAD: presenilin-1 (PSEN1) 
(Levy-Lahad, 1995) and presenilin-2 (PSEN2) (Sherrington et al. 1995). These genes encode 
highly homologous, ubiquitously expressed multiple transmembrane domain proteins in 
which a vast number of mutations have been identified in FAD families. Several years 
passed before the AD field determined that PSEN1 and PSEN2 were integral parts of the 
elusive gamma-secretase (De Strooper et al. 1998). Finally, a series of seminal reports 
provided independent evidence supporting the hypothesis that presenilins provided the 
catalytic core of gamma-secretase (De Strooper et al. 1999, Struhl & Greenwald 1999, 
Wolfe et al. 1999). This was ultimately proven by the finding that transition-state, gamma-
secretase inhibitors, targeted the presenilins (Esler et al. 2000, Li et al. 2000). The protein 
composition of the gamma-secretase complexes is now largely resolved (De Strooper 
2003). The different gamma-secretases each consist of at least four proteins that are all 
required for proteolytic activity (Edbauer et al. 2003, Kimberly et al. 2003): APH-1, PEN2, 
and nicastrin (Edbauer et al. 2003; Yu et al. 2000). In contrast with this basic knowledge, 
tantalizing questions regarding the physiology, the cell biology, and the structure-
function relation of these intriguing gamma-secretases will keep research groups around 
the world busy for several years largely because the normal function(s) of the presenilins, 
and other protein components that make up the gamma-secretase complex, remains 
unclear. PSEN1 knockout mice die in utero and have a phenotype similar to that of Notch 
(another single-pass transmembrane domain protein) knockout mice (Thinakaran, 2002). 
However, what is clear is that the gamma-secretase complex directly cleaves the C-
terminal transmembrane protein stubs of Notch, APP, APLPs and many other substrates. 
The mechanism by which gamma–secretase cleaves its substrates is not the focus of this 
chapter and the process has been described in great detail elsewhere (De Strooper & 
Annaert, 2010). Here we focus on the normal biological function of the presenilins which 
has been difficult to determine largely due to the fact that in mammals, it is an essential 
gene and knockout mice die in utero. 
2.2.2 The role of presenilins in higher organisms 
Notch is a protein involved in cell fate decisions during development and consequently 
the Notch field of research continues to provide novel insights into various cellular 
physiological processes, including the biology of the presenilins (Kopan & Ilagan 2009). 
Furthermore, the central role of presenilin-dependent gamma-secretase activity in Notch 
signaling has been unequivocally demonstrated in a long series of genetic experiments in 
various organisms including flies and worms (Levitan & Greenwald, 1995). In mammalian 
species, the situation is much more complicated because of gene duplication (PSEN and 
APH-1) and embryonic lethality of knocking out the PSEN and Aph-1 genes (Ma et al. 
2005). Moreover, in adult animals, partial or tissue-specific knockouts of PSEN-1 lead to 
gastrointestinal bleeding, hair-color changes, and immune problems (Tournoy et al. 2004). 
In addition, more than 60 other proteins have been proposed or identified as substrates 
for the gamma-secretases (McCarthy et al. 2009, Wakabayashi & De Strooper 2008). 
Almost all candidates are type I integral membrane proteins, and they obey the same 
consecutive-cleavage process as was outlined for APP and has suggested that in many 
cases, the whole PSEN1 process is aimed at clearance of transmembrane domain stubs 
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from the cell membrane. Protein transport and turnover has also been suggested as a 
function of presenilin based upon work indicating that several members and/or effectors 
of the Rab family of small GTPases interact with PSEN (Dumanchin et al. 1999). Most 
recently it was suggested that PSEN1 is involved in the maturation of the V0a1 subunit 
and subsequent assembly of the V-ATPase proton pump, providing an explanation for the 
defects in acidification of cellular degradative compartments in Psen knockout cells (Lee et 
al. 2010). Despite a number of reports suggesting that PSEN mutations also affect Ca2+ 
signaling by disturbing the Ca2+ pool in the ER (Bezprozvanny & Mattson 2008), the 
origin of this disturbance is highly debated, contradictory and the literature remains 
confusing. What is true is that more is known about the function of presenilin substrates 
and their intracellular cleavage domains (ICDs) than presenilin itself (reviewed in 
Krishnaswamy et al. 2009). Of particular importance regarding this chapter, the function 
of PSEN-dependent gamma-secretase in more distantly related and unicellular species has 
not been demonstrated or explored to any comparable extent. PS-like components have 
been identified in moss (Khandelwal et al. 2007), but gamma-secretase activity could not 
be detected. Overall, a lot of difficult work is still needed in order to decipher the function 
of presenilin in different gamma-secretase complexes in mammals, but to also uncover the 
normal in vivo role of the protein in other readily available model systems including lower 
organisms. 
2.2.3 The identification of presenilins and gamma-secretase activity in Dictyostelium 
A recent development in Dictyostelium biomedical research was the identification of 
homologous genes to presenilin 1, presenilin 2, nicastrin, aph-1 and pen-2, the core 
components that constitute the gamma-secretase complex (McMains et al. 2010). As 
discussed in humans, mutations in the presenilins, which are integral for protease activity 
are intimately involved in the aberrant proteolytic processing of APP in a pathway that 
leads to the condition of early onset familial Alzheimer disease. How the defects cause 
disease, or more importantly the time course or precipitating events that lead to the 
pathogenesis of AD are not known, and as such, highlight the importance of uncovering the 
normal function of the gamma-secretase complex responsible for production of the toxic 
Abeta peptide. In this section, I discuss the importance of having a viable, organismal 
model, to aid in further understanding the normal physiological role of the presenilins and 
gamma-secretase from a conserved and evolutionary point of view in a system that has no 
Notch or APP equivalent (Eichinger et al. 2005). To study the gamma–secretase in 
Dictyostelium in great detail, strains were created containing single and/or double gene 
disruptions for ps1-, ps2-, aph1-, ncst- and ps1/ps2-, aph1/ps2-, ncst/ps2-, and aph/ncst- nulls. It 
is important to note that mutants of these genes in Dictyostelium are viable, unlike the 
embryonic lethality seen in mammalian systems, and that mutant amoebae show a variety 
of phenotypic defects during specific periods of development. Moreover, extensive sequence 
analysis reveals that the Dictyostelium presenilins are structurally similar to proteases in this 
family of proteins rather than the related signal peptidyl proteases (SPP) and that 
phylogenetic analysis firmly places them among this group (Figure 2A-D), and a majority of 
the mutations in the human PS1 gene associated with early-onset familial Alzheimer’s 
disease alter residues (Kim & Kim, 2008) that are conserved in both Dictyostelium PS proteins 
(McMains et al. 2010).  
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Fig. 2. Dictyostelium PS proteins align with human presenilins. (A) Phylogenic comparison 
of amino acid sequences of Dictyostelium and the human PS and signal peptidyl proteases 
(SPP) proteins. The Dictyostelium PS proteins cluster closely with human PS. (B-D) 
Sequence alignments of functional domains of PS and SPP proteins. Similar amino acid 
residues are indicated in red. Residue alignment surrounding the N-terminal enzymatic 
aspartate (*) is shown. Residue alignment surrounding the C-terminal enzymatic aspartate 
(*) is shown. Residue alignment within the conserved, overlined PALP domain region. 
Permissions: McMains, V.C. et al. (2010). Dictyostelium possesses highly diverged 
presenilin/gamma-secretase that regulates growth and cell-fate specification and can 
accurately process human APP: a system for functional studies of the presenilin/gamma-
secretase complex. Dis. Model. Mech. 3, pp. 581-594. 
2.2.4 The presenilin gamma–secretase complexes regulate cell differentiation and 
phagocytosis in Dictyostelium 
Cells deficient for ps1 did not show post-aggregative developmental defects compared to 
cells deficient for ps2 suggesting that in Dictyostelium, PS1 gamma–secretase complexes may 
carry out different functional activities than PS2 gamma–secretase complexes during specific 
phases of the life cycle. This observation fits well with the suggestion that that there may be 
several distinct presenilin complexes that have different biological activities (Gu et al. 2004). 
Wild type and ps1- cells are able to complete development within 24 hours, whereas ps2-, 
aph1- and ncst- mutants not only form fewer fruiting bodies, but predominantly arrest as 
abnormal intermediate structures within the same time frame (McMains et al. 2010). It 
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should be noted that the observed development defects were more pronounced in the 
double mutants and so PS1 might also contribute some functional activity during 
development. The authors also show that in Dictyostelium gamma-secretase complexes 
function to regulate cell differentiation as measured by cell-type specific gene expression 
and firmly establish that PS gamma–secretase activity is required in a cell-autonomous 
pathway that determines cell fate during development (McMains et al. 2010). Once again, 
these in vivo observations support a large body of suggestive evidence for presenilin 
gamma–secretase playing an essential role in cellular and neuronal differentiation during 
neural development and adult neurogenesis in mouse and zebrafish models (Baumeister, 
1999; van Tijn, 2011). The authors also found that cells deficient for gamma-secretase display 
a reduced ability for phagocytosis. Quantification of phagocytic rates for the various mutant 
strains in comparison to wild type cells revealed that cells lacking PS1 had highly reduced 
rates of phagocytosis, but this was not the case for ps2- cells. The described phagocytosis defect 
supports observations that mammalian presenilins are present in lysosomal membranes, but 
also strengthens the argument that distinct presenilin complexes exist and have different 
biological activities. Further to this, when wild type amoeba were made to express a variant of 
human APP, the cells were clearly able to process APP in a manner identical to mammalian 
cells resulting in the differential production of C-terminal fragments and Abeta40/Abeta42, 
the toxic fragment believed to be the causative agent in AD (Figure3).  
This work demonstrates the evolutionary conservation of this key regulatory enzyme and 
establishes the ability to now use the powerful molecular genetics of Dictyostelium to test a 
variety of biochemical predictions using an in vivo system. Therefore the most obvious value 
stemming from this work for the study of presenilin cellular functions and neurological 
disease falls into three categories. The first being the development of a viable organismal 
system to study both the ancient and conserved function(s) of the presenilin-dependent 
gamma-secretase complex, and the possibilities for elucidating presenilin-independent 
function(s) (Neely et al. 2011); secondly, the exciting prospects surrounding the finding that 
proteolytic processing of APP occurs in Dictyostelium exactly the same way as has been 
shown animal cells. This finding is important not only because it provides an excellent 
system in which to test therapeutic agents that target Abeta production in vivo, but it is 
remarkable that this enzyme, given the evolutionary distance between Dictyostelium and 
humans, is capable of cleaving a non-endogenous substrate to produce C-terminal 
fragments and ratios of secreted Abeta40/Abeta42 identical to mammalian systems. It 
should be mentioned that a survey of the Dictyostelium genome does not readily identify or 
predict the presence of either the known alpha–secretase or beta–secretase (BACE) 
(Eichinger et al. 2005) and suggests the presence of yet to be identified first-cleavage 
sheddases either unique to Dictyostelium or potentially conserved across metazoan species. 
Moreover, this model offers a biochemical clarity not offered by any other system to date to 
study gamma–secretase function directly, free from the multiple secondary effects that can 
arise from perturbation of proteolysis of more than 60 identified substrates (McCarthy et al. 
2009). Experiments will need to be conducted to elucidate the mechanism by which 
Dictyostelium produces gamma–secretase targets from human APP in the absence of these 
characterized mammalian enzymes. Unfortunately, from the point of view of therapeutically 
targeting gamma-secretase it may also suggest that this enzyme is indeed a “membrane 
proteasome” with less stringent substrate requirements for target specificity than previously 
thought (Hemming et al. 2008). Clearly, this work further demonstrates the importance in 
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understanding how gamma-secretase complexes recognize and differentiate between their 
many substrates which undoubtedly are essential for understanding the role of presenilins 
in biological processes. Lastly, this study provides strong in vivo evidence for presenilin 
function in regulating phagocytosis, only previously suspected in animal cell culture (Jutras 
et al. 2005). Further studies will be required to determine whether the mammalian PSEN 
gene can rescue Dictyostelium ps1-null phenotypes and proteolytic processing of human 
APP. 
 
Fig. 3. Dictyostelium have PS-dependent gamma-secretase activity that processes human 
APP to release Abeta peptides. (A) Schematic showing various APP derived products and 
their respective sizes. (B) ΔN-APP, a truncated human APP expressed in transformed wild 
type (WT) and ps1-null cells were analyzed for secreted levels of Abeta40 and Abeta42 
peptides by quantitative ELISA. Fresh media and media conditioned by native WT cells 
were used a negative controls. Bars indicate standard errors derived from two independent 
experiments, each with two replicates. (C) Protein samples were collected from native and 
APP-expressing CHO cells untreated or treated with DAPT, from growing WT Dictyostelium 
or WT, aph1-null and ps1/2-null Dictyostelium that express ΔN-APP. APP expression and 
processing was determined by immunoblot assay using anti-APP C-terminus antibodies. 
Permissions: McMains, V.C. et al. (2010). Dictyostelium possesses highly diverged 
presenilin/gamma-secretase that regulates growth and cell-fate specification and can 
accurately process human APP: a system for functional studies of the presenilin/gamma-
secretase complex. Dis. Model. Mech. 3, pp. 581-594. 
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2.3 Huntington’s disease 
Huntington’s disease (HD) is a fatal neurodegenerative disease (HD Collaborative Research 
Group, 1993) also known as Huntington’s chorea, that affects muscle coordination and leads 
to cognitive decline, dementia and eventually death. The molecular mechanisms underlying 
the disease have been widely studied yet the normal function of the protein responsible for 
the disease remains largely unknown. HD is a monogenic neurological disorder that occurs 
because of a mutation in the huntingtin protein (HTT). The disease is caused by an unstable, 
but normally polymorphic, CAG trinucleotide repeat within the coding region of the htt 
gene that leads to the expansion (>35) of a homopolymer stretch of glutamine (Q) residues 
near the amino-terminus of the protein (HD Collaborative Research Group, 1993). Mutant 
HTT confers a gain-of-function property to some aspect of the protein, but recent evidence 
also suggests that mutant HTT impairs the ability of normal huntingtin protein to exert 
molecular activities that are fundamental for the survival and functioning of the neurons 
that predominantly degenerate in the disease (Cattaneo et al. 2005). Huntingtin is a large 
(350 kDa) alpha-solenoid HEAT (huntingtin, elongation factor 3, the A subunit of protein 
phosphatase 2A, and TOR1) repeat protein (Andrade & Bork, 1995) that bears little 
resemblance to any known protein. After almost 20 years of research and more than 13,000 
research articles, the normal function of HTT, which is expressed in all cells, both neuronal 
and non-neuronal, still remains unclear for a number of reasons (reviewed in Zuccato et al. 
2010).  
The large size of HTT makes it challenging to perform biochemical experiments and develop 
robust structure/function assays. Manipulating such a large DNA fragment by conventional 
molecular cloning techniques is fraught with problems including sequence stability in 
bacterial hosts, expansion/contraction of the polyQ and deletions of the polyproline region. 
Consequently, few studies have been able to address the cellular function(s) of full-length 
HTT and its dysfunction(s) associated with the disease compared to the vast amount of 
literature on the amino-terminal fragment, which in essence, removes the mutation from the 
context of the full-length protein. One might be inclined to argue that studying N-terminal 
polyQ fragments is tantamount to research on polyQ disease rather than HD. However, the 
point of this chapter is not to create controversy as one cannot deny that much has been 
learned about HTT fragment toxicity in studies that utilize the N-terminal fragment. The 
few genetically precise mouse models for HD (knock-in mice that harbor the full-length 
mutant protein) have contributed significantly towards understanding HTT normal 
function, but these mice are laborious to create, expensive to maintain and the results 
expensive and difficult to validate. Moreover, sub-cellular localization, which often provides 
clues to protein function, has also been an arduous task due to conflicting reports between 
various antibodies and the effects that different immunocytological methods can have upon 
the apparent location of HTT in the cell (reviewed in Hughes & Jones, 2011). Lastly, a 
number of methods are available to map protein-protein interactions as a means to elucidate 
protein function. With each approach come strengths and weaknesses regarding specificity 
and/or sensitivity of the interaction, and again in the case with HTT, its large size and 
differential affinity for a variety of antibodies has made uncovering its normal function 
difficult to interpret. As such, a single large scale screening experiment identified at least 234 
proteins that interact with mutant huntingtin (Kaltenbach et al. 2007). In this study, the 
authors assessed five different recombinant wild type and mutant HTT fragments spanning 
the length of the protein using yeast two-hybrid (Y2H) and affinity pull-down/mass 
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spectrometry (MS) protein interaction screens. How these interacting partners ultimately 
contribute to understanding HTT normal function remains to be seen, and again, the 
interpretation of the results must be closely scrutinized as the screen used fragments and 
was not performed with full-length HTT, which when mutated, is the actual causal agent of 
HD. 
2.3.1 Higher organism and cellular models of Huntington’s disease 
Genetic evidence in humans and mouse models of Huntington’s disease suggests that the 
disease mutation acts through the deregulation of some aspect of the protein’s normal 
function(s). Over time, the consequence of carrying the HD mutation is an extensive amount 
of neurodegeneration characterized by the preferential loss of efferent medium spiny 
neurons in the striatum of the basal ganglia. This massive amount of neuronal loss is 
primarily responsible for the typical HD symptoms (Reiner et al. 1988). However, it is now 
well known that as the disease progresses, a more widespread degeneration of the brain 
ensues and also involves cortical structures (Rosas et al. 2003, 2005). Thus, defining the 
disease-producing ‘gain-of-function’ - either a polyglutamine-length dependent increase or 
deregulation of a normal huntingtin activity or the introduction of a novel polyglutamine-
length dependent activity, will without a doubt require an understanding of the protein’s 
normal function(s) beyond what is currently feasible methodologically when using post 
mortem human brain samples.  
I will now offer a brief look at the wide range of HD animal models currently available to 
the HD community. These models have been used to investigate pathological pathways, 
molecular targets, and potential therapeutics. A wide variety of species, including 
invertebrates such as Drosophila melanogaster, non-mammalian species (e.g., Danio rerio) and 
mammals, including mice, rats, sheep and non-human primates, have also been genetically 
engineered to model the HD mutation. Unfortunately, many of these models, that express 
either truncated or full-length human or mouse mutant huntingtin, display significant 
phenotypic discrepancies within species that are often attributed to differences in strains or 
protein context (HTT fragments vs full-length). However, with their size, organ capacity, 
and close resemblance to human physiology, these models are particularly well-suited for 
preclinical trials and long-term safety studies. The limitations associated with these models 
are often ethical concerns, the fact they take a considerable amount of time (e.g., years) to 
assess and are incredibly costly to maintain. Moreover, modeling the HD mutation, a human 
disease and without knowing the normal function of the protein, relies primarily on re-
creating human symptoms in non-human systems. Although these systems are extremely 
important tools to understand HD, a large majority of studies focus upon the late end-stage 
disease symptoms and thus offer minimal insight into early manifestation including HTT 
normal function. An attempt to describe the phenotypic differences between these entirely 
different model systems is well outside the scope of this chapter and can be reviewed 
elsewhere (Zuccato et al. 2010). The existence of HD cell lines, which allow for the stable or 
inducible expression of wild-type or mutant huntingtin, have been, to a finite degree, useful 
for the dissection of huntingtin function and assessment of potential therapeutic compounds 
(Rigamonti et al. 2007; Varma et al. 2007). Further, in vitro cell lines often do not show overt 
defects suggesting they are unable to reproduce the pathophysiological mechanisms 
induced by the mutant gene.  
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I have established that the dominant nature of Huntington’s disease (HD) and its tissue 
specificity relative to the fact that it is ubiquitously expressed indicate that the HD mutation 
may initiate pathogenesis through some unique characteristic activity of the huntingtin 
protein, making it critical that we understand the normal biochemical function(s) of 
huntingtin. This is true with respect to developing safe effective treatments. However, the 
truth is, we don’t currently know the details of huntingtin’s function nor do we have a ready 
assay for its rapid and accurate assessment. As mentioned earlier, many established model 
systems are based upon an amino-terminal fragment that results in perturbation of many 
cellular processes but these remove the polyglutamine tract from its normal protein context. 
Therefore, one cannot understate that strategies are badly needed to reveal full length 
huntingtin-dependent biochemical processes that contribute to HD pathology. Because of 
the evolutionary conservation of huntingtin, lower organism systems offer an attractive and 
affordable route that has yet to be exploited to understand huntingtin function. 
Consequently, we have used the model organism Dictyostelium to generate a viable 
huntingtin-null organism and have defined the various phenotypes.  
2.3.2 The identification of Dictyostelium huntingtin 
Use of the social amoeba Dictyostelium to uncover normal function(s) for HTT with a 
particular focus on the importance of how these functions might illuminate our total 
understanding of the early vulnerability of specific neuronal populations to mutant HTT is 
the long-term goal that requires validation in cross-species HTT-null mutants and in vitro 
cell lines. The Dictyostelium genome was screened and found to contain a single gene with 
sequence homology to human huntingtin. Bioinformatic and phylogenetic analysis of the 
primary amino acid sequence placed the protein firmly within the huntingtin family, 
including size, and the presence of numerous HEAT and HEAT-like repeats. In developing 
mutants’ deficient for HTT we have determined that in Dictyostelium, cells are viable, unlike 
the embryonic lethality seen in higher eukaryotes. Moreover, htt- cells are fragile in that they 
display a number of subtle phenotypes which suggests that HTT is involved in a number of 
cellular processes (Myre et al. 2011). We show that huntingtin deficiency impacts upon 
growth, osmoregulation, cation homeostasis, cell motility, cell shape, chemotactic cAMP 
relay, homotypic cell-cell adhesion and cell fate determination in Dictyostelium. Importantly, 
these phenotypic deficits are greatly dependent upon the environment in which the cells are 
placed which suggests that HTT may serve as a multifunctional protein that aids in 
translating extracellular signals into cellular processes. These findings support the large 
body of evidence that suggest in metazoa, huntingtin is a multifunctional protein with 
suggested roles in embryogenesis, cell fate, cytoskeleton, apoptosis, BDNF production and 
signaling, vesicular and mitochondrial transport, iron homeostasis, autophagy, energy 
metabolism and transcriptional regulation (Cattaneo et al. 2005; Lumsden et al. 2007; 
reviewed in Imisario et al. 2008). Major issues of concern regarding HTT function is the 
inability to discern if these hypotheses correlate with each other, are mutually exclusive to 
one another, and which, if any, directly involve HTT or are secondary effects to HTT 
deficiency or mutant HTT activity. The power behind the Dictyostelium system is that it 
allows for the identification of different in vivo HTT functions at the level of both single cells 
and a multi-cellular environment all in the same organism and with a biochemical and 
cellular clarity that will identify functions that directly depend on HTT. 
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2.3.3 Dictyostelium cells deficient for huntingtin display cell shape and 
osmoregulatory defects 
When htt- cells are induced to develop under non-nutrient, low ionic strength phosphate 
buffer (KK2; ~40 mOsmol/L), the cells immediately elicit a round phenotype suggesting the 
presence of an actin-cytoskeleton defect, and a role for HTT in modulating the ability of cells 
to adapt to stress or changes in their ionic environment (Myre et al. 2011). Under these 
conditions and in large contrast to wild type cells, HTT-null cells show a disorganized 
cytoskeleton with a reduction of F-actin at the cortex of the cell (Figure 4A-D). This fits well 
with reports that mutant HTT in cells from HD patients or when normal huntingtin levels 
are reduced cells display defective actin-remodeling under conditions of stress (Munsie et 
al. 2011). In vitro binding of the HTT N-terminus to F-actin has been reported (Angeli et al. 
2010). Together with our in vivo observations indicates a normal, perhaps transient, function 
for HTT in the regulation of the actin cytoskeleton. Considering the importance of 
extracellular tonicity to neuronal function, this model provides a valuable tool to uncover 
mechanisms by which HTT regulates intracellular ionic stores. The extreme cell rounding 
observed in low osmotic buffer also hinted at a potential defect in osmoregulation. In 
Dictyostelium, osmoregulation is maintained by a bladder-like intracellular membranous 
organelle called the contractile vacuole (CV) that also functions as a highly efficient acidic 
Ca2+-store (Zhu & Clarke, 1992). When wild-type cells are placed in water, several small 
contractile vacuoles form within 30 minutes and, over time, the cells compensate for the 
sudden change in their osmotic environment, whereas htt- cells fail to form vacuoles, rapidly 
swell and undergo complete lysis within 5-6 hours (Myre et al. 2011) (Figure 4E). This 
finding is conducive with the role of the cortical cytoskeleton and F-actin crosslinking 
proteins that protect cells against osmotic stress ensuring both cell size and shape, and 
suggests a scaffolding role for HTT between the cytoskeleton, actin-remodeling proteins and 
the function of the CV system in Dictyostelium. These results are also consistent with 
mammalian studies that huntingtin regulates neurological processes including actin-rich 
dendritic spine formation and membrane branching (Dent et al. 2011; Ferrante et al. 1991). 
We suggest that the defective CV system in htt- cells renders cells not only sensitive to 
extreme hypoosmotic shock, but secondarily affects intracellular ion homeostasis. As a 
consequence, unless specific cations (Ca2+ or Mg2+) are provided exogenously htt- cells appear 
unable to initiate cAMP-induced Ca2+-transients that may act in a feedback loop to positively 
reinforce cAMP relay which impairs chemotaxis during Dictyostelium development. Although 
a role for HTT in chemotaxis has not been established in mammalian systems, a consensus is 
gradually emerging that the dyshomeostasis of Ca2+ is an important factor in the linkage of the 
HTT mutation to the onset and progression of the disease (reviewed in Bezprozvanny, 2007) 
and together suggest abnormal Ca2+ signaling and other Ca2+ signaling proteins should be 
explored further as an evolutionary conserved role for HTT. 
2.3.4 Huntingtin regulates cell fate and differentiation during development in 
Dictyostelium 
Furthermore, this study also provides compelling evidence to suggest HTT modulates cell 
fate and differentiation in Dictyostelium (Myre et al. 2011) (Figure 5). Using chimeras, we 
have shown that when htt- cells are challenged to differentiate in the presence of wild type 
cells, they fail to populate the prespore region of the slug, and as a consequence do not 
become spores. Differentiation defects in huntingtin deficient cells during development has 
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also been observed in vertebrates. In zebrafish, reduced expression of huntingtin 
differentially targets development of telencephalic neurons compared to mid- and hind-
brain (Henshall et al. 2009). In mouse chimeras, Hdh-/- cells also preferentially colonize  
the hypothalamus, midbrain, and hindbrain relative to the telencephalon and the  
thalamus during early development (Reiner et al. 2001). Thus, like these latter neuronal  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Htt- cells round up under nutrient stress affecting F-actin localization and fail to 
osmoregulate. (A) The morphology of htt- cells as an adherent culture was similar to wild-
type cells (left panel). (B) Removal of nutrients and replacement with starvation buffer 
caused rounding of htt- cells. (C) F-actin staining (red) in wild type and htt- cells is similar. 
(D) Aberrant localization of F-actin occurs in starved htt- cells. Nuclei are counterstained 
with Hoechst 33342 (blue) (E) Unlike WT cells (left) htt- cells are extremely sensitive to 
hypoosmotic shock, and begin to lyse after ~3 hours. Permission: Myre M.A. et al. (2009). 
Deficiency of huntingtin has pleiotropic effects in the social amoeba Dictyostelium discoideum. 
PLoS Genetics, 7(4), pp. e1002052. 
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populations, Dictyostelium cells require huntingtin for the proper development of viable 
spores in the presence of wild-type cells. Not surprisingly, the data thus far do not provide a 
simple definition for a single normal function for huntingtin, but, as huntingtin deficiency in 
Dictyostelium produces pleiotropic effects throughout the life cycle, the findings are 
consistent with the consensus from mammalian studies that huntingtin is a multifunctional 
protein that can impact upon many biochemical processes. Importantly, the existence of a 
Dictyostelium ortholog of human huntingtin, the viability of the null htt- mutant, and its 
discrete, readily assayed deficiency phenotypes indicate that this haploid organism provides 
an effective genetic model system to identify molecular and cellular processes affected by 
the loss of huntingtin function. Exciting new avenues of research have emerged in 
delineating which of these functions are conserved in mammals. Ultimately, determining to 
what degree these functions are altered by expansion of the polyglutamine tract in human 
huntingtin will also provide much needed insights into the mechanism by which mutant 
huntingtin triggers HD pathogenesis. 
 
Fig. 5. Huntingtin regulates prespore/spore differentiation cell-autonomously. (A) 
Schematic representing the position and distribution of cell types in the slug. The prestalk 
(front) and prespore (rear) domains are underlined. Cell types within each region are shown. 
(B) GFP was expressed in htt- cells and their position in chimeras with unlabelled wild type 
cells was monitored. GFP:htt- cells fail to populate the prespore domain. (C) Reverse 
experiment in which GFP: WT cells in chimeras with unlabelled htt- cells occupy the 
prespore domain. Permission: Myre M.A. et al. (2009). Deficiency of huntingtin has 
pleiotropic effects in the social amoeba Dictyostelium discoideum. PLoS Genetics, 7(4), pp. 
e1002052. 
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2.4 Hirano bodies – Dictyostelium as the first available cultured cell model of Hirano 
bodies 
Hirano bodies, first described more than 40 years ago, are bright eosinophilic 
intracytoplasmic inclusions/protein aggregates which have a highly characteristic 
crystalloid fine rod structures that occur preferentially in the neuronal processes of 
individuals with a number of neurodegenerative diseases including Alzheimer's disease, 
Creutzfeldt-Jacob disease, amyotrophic lateral sclerosis, parkinsonism-dementia and Pick’s 
disease (Cartier et al. 1985; Hirano, 1995). Therefore, Hirano bodies are largely considered as 
a pathological hallmark of postmortem brain samples from patients suffering from 
neurodegenerative disorders and thus represent “tombstones” that mark neuronal cell 
death. Although Hirano bodies are most often encountered in neurons of the central 
nervous system, they have been reported in glial cells, in peripheral nerve axons, and in 
extraocular muscles of eyes (Tomonaga, 1983) suggesting that they may be more than 
products of cell death. It should be noted that Hirano bodies are also increasingly observed 
as a function of age in individuals without any obvious underlying neurodegeneration 
(Gibson & Tomlinson, 1977). The importance of these findings remains to be addressed. 
Hirano bodies are complex neuronal inclusions comprised of a variety of proteins including 
actin and actin-associated proteins (cofillin and alpha–actinin), tau, a C-terminal fragment of 
APP, microtubule associated bundling proteins (MAPs), and neurofilament proteins 
(Hirano, 1994). Moreover, they are not specific to humans and have been described in 
various experimental animals. Although their existence has been reported for decades, 
understanding the underlying pathological molecular mechanism responsible for their 
formation has been precluded by the lack of either an in vitro or in vivo experimental model 
system. In this section I highlight the development of Dictyostelium as the first available 
cultured cell model of Hirano bodies (Maselli et al. 2002). Of critical importance here is that 
research using Dictyostelium has shown that the formation of Hirano bodies is a pathological 
event and not simply related to cell death. 
I have already established that abnormal protein aggregation results in formation of distinct 
types of protein assemblies frequently associated with neurodegenerative disease. Maselli et 
al. 2002 managed to show that expression in Dictyostelium of the CT fragment (amino acids 
124-295) of the 34 kDa protein, a protein that exhibits activated actin binding and calcium-
insensitive actin filament cross-linking activity induced cells to form ellipsoidal 
paracrystalline inclusions that contain ordered assemblies of F-actin, CT-myc, myosin II, 
cofilin and alpha-actinin that remarkably resembled the structure of Hirano bodies. They 
extended their findings to mammalian murine cells and discovered that F-actin 
rearrangements caused by a reduction in stress fibers accumulate as numerous punctate foci 
and large aggregates: Hirano bodies (Maselli et al. 2002). This suggested that the failure to 
regulate either the activity and/or affinity of an actin cross-linking protein can provide a 
signal for formation of Hirano bodies. Whereas wild type cells complete development in 24 
hours, they found that CT-myc cells contained significantly higher amounts of F-actin, were 
able to form fruiting bodies, but displayed delayed developmental timing by ~6 hours. 
Further to this, an accumulation of F-actin was also shown to occur in murine cells 
expressing CT-myc. More importantly, this first report established for the first time that 
formation of Hirano bodies is not restricted to mammalian cells or nerve cells, occurs as a 
consequence of aberrant function of the actin cytoskeleton and demonstrated the 
physiological effects that Hirano bodies can exert on normal cell function. Because of the 
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development of this system using Dictyostelium, the formation of Hirano bodies and 
induction of F-actin rearrangements in mammalian cell cultures by expression of the CT 34-
kDa actin-bundling protein has now been shown to occur in HEK 293, HeLa, Cos7 cells, 
neuroblastoma and astrocytic cells, and in primary neurons (Davis et al. 2008). 
The abundant detection of Hirano bodies in numerous neurodegenerative diseases suggest 
the complex aggregate might be involved in normal and neuronal disease processes. This 
prompted the study to determine how Hirano bodies are turned over in the cell. Hirano 
bodies in cultured mammalian cells are frequently observed within membrane-bound 
vesicles and therefore suggested they might be degraded by autophagosomes. Strains of 
Dictyostelium mutants with defects in autophagy and the use of proteasome inhibitors 
revealed that these aggregates are turned over by autophagic processes as well as the 
ubiquitin-proteasome pathway (Kim et al. 2009). Importantly, the authors were able to also 
show that Hirano bodies are also turned over in human H4 cells by both the proteasome and 
autophagy. These studies support the concept that the ability of clearance mechanisms to 
keep pace with accumulation of aggregates may have a major impact on disease progression 
and further showcase how the lower eukaryote Dictyostelium can be used to gain novel 
insight into mechanisms that potentially contribute to human neurodegenerative disease. 
3. Pharmacogenetics 
Pharmacogenetics is generally regarded as the study or clinical testing of genetic variation 
that gives rise to differing response to drugs, while pharmacogenomics is the broader 
application of genomic technologies to new drug discovery and further characterization of 
older drugs. Pharmacogenetics refers to genetic differences in metabolic pathways which 
can affect individual responses to drugs, both in terms of therapeutic effect as well as 
adverse effects. This section will discuss in detail, the discovery that Dictyostelium naturally 
produces small-molecules with anti-amyloidogenic properties and therefore serves as a 
valuable resource of novel compounds with the potential to become lead molecules in 
clinical trials with the long-term goal of treating neurodegenerative diseases such as AD. 
Importantly, Dictyostelium can serve as a high-throughput in vivo tool with the potential to 
identify common modes of action, toxic and therapeutic dosing and adverse effects with 
greater biochemical clarity than in vitro screening methods. One may even argue that in 
some cases, the use of this model system has the potential to rapidly and cost-effectively act 
as proof-of-principle for future validation studies to improve the safety of certain drugs. 
Very early during the development and clinical analysis of new pharmaceuticals, it is 
imperative to determine the teratogenic potential of promising drugs. Dictyostelium has 
successfully been used as a simple biological system to study the teratogenic effects of 
valproic acid (VPA) and valproic acid-analogues with results that are consistent with data 
obtained in mammalian teratogenicity assays (Dannat et al. 2003; Tillner et al. 1998). In 
keeping with this, Dictyostelium has also provided much needed detailed insight into the 
common mechanistic action of specific neuropsychiatric therapies for bipolar disorder 
including lithium and VPA, whose mode of action remains poorly understood (R.S. 
Williams et al. 2002). Early work was able to show that in Dictyostelium, drugs that provide a 
neuroprotective effect in individuals with bipolar disorder work through a common 
mechanism involving the activation of MAPK signaling and increased ERK2 
phosphorylation by reducing protein kinase A (PKA) signaling (Eickholt et al. 2005). More 
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recently, data from Dictyostelium models strongly suggest that VPA rapidly immobilizes 
phospholipid signaling through the modulation of phosphoinositide levels independent of 
inositol regulation which coincides with a reduction in endocytic trafficking and that VPA 
when tested in mammalian cells also abrogates this process as measured through 
depolarization-dependent neurotransmitter release in rat nerve terminals (Chang et al. 2011; 
Xu et al. 2007). The use of Dictyostelium as a model system to understand the common 
mechanism of action of drugs to treat bipolar disorders will not be discussed any further in 
this chapter as it has been recently and extensively reviewed (Ludtmann et al. 2011) but 
confirms the existence of conserved drug-sensitive signaling pathways between 
Dictyostelium and mammalian model systems. 
3.1 Differentiation-Inducing Factor-1 from Dictyostelium has anti-amyloid properties 
As discussed earlier in this chapter, many theories regarding the pathogenesis of AD 
resulting in abnormal Abeta production or clearance that include inflammation, oxidative 
stress, metal ion dysregulation and Ca2+-dyshomeostasis, but the exact mechanisms leading 
to Abeta accumulation remain unclear (reviewed in Walsh & Selkoe, 2004). However, more 
and more evidence has suggested that irregular cell cycling in selective neuronal 
populations may contribute to the initiation of AD pathogenesis (reviewed in Herrup & 
Arendt, 2002; Nagy et al. 1998). Although a controversial area of AD research given the post-
mitotic nature of neurons, a variety of cell cycle regulatory proteins, including proliferating 
cell nuclear antigen, cyclin  
 
Fig. 6. Chemical structure of DIF-1. Differentiation-Inducing Factor-1 (DIF-1) (l-[3, 5-
dichloro-2, 6-dihydroxy-4-methoxyphenyl]-l-hexanone) is a chlorinated alkyl phenone, 
isolated from the social amoeba Dictyostelium discoideum. Permission: Myre M.A. et al. 
(2009). Reduced amyloidogenic processing of the amyloid beta-protein precursor by the 
small-molecule Differentiation Inducing Factor-1. Cellular Signalling, 21(4), pp. 567-76. 
D1, Cdk4, and cyclin B1, are often detected in animal models of AD well before the presence 
of plaques, and in human brain regions that display AD pathology (Khurana et al. 2006; 
Yang et al. 2006). Even though APP processing is clearly aberrant in neuronal signaling 
pathways, the relevance of neuronal cell cycle re-entry to this process remains unclear. 
Interestingly, APP processing is elevated in pancreatic cancer, oral squamous cell 
carcinomas and colon carcinomas, which strongly suggest that APP proteolysis is linked to 
physiological processes involving cellular proliferation and that treatment of cells with 
antisense oligonucleotides against APP reduced both secreted APP and proliferation 
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(Hanzel et al. 2003; Ko et al. 2004). Collectively, it would appear that genetic and/or 
environmental factors (e.g., oxidative and metabolic insults on brain aging) that impede 
upon the tight regulation of the cell cycle could indeed impact upon Abeta formation. I 
spoke earlier in this chapter on the various uses of Dictyostelium to understand eukaryotic 
cellular processes and the role that secretion of small chemical morphogens have on the 
coordinated cellular differentiation of amoeba into prestalk or prespore cells (J.G. Williams et 
al. 1989). One particular morphogen is a unique chlorinated alkyl phenone, (l-[3, 5-dichloro-2, 
6-dihydroxy-4- methoxyphenyl]-l-hexanone) which has been termed Differentiation-Inducing 
Factor-1 (DIF-1) (Figure 6) (Kay & Jermyn, 1988). Even though the intracellular DIF-1 
receptor(s) have yet to be identified in Dictyostelium, and no structural analogs of DIF-1 have 
been reported in mammalian systems, novel functions for DIF-1 in inhibiting the proliferation 
of mammalian tumors concomitant with decreased expression of specific cell cycle markers 
(e.g., cyclin D1 and beta-catenin) have been reported (Yasmin et al. 2005). Of particular interest 
and in support of the role of APP in cellular proliferation was the finding that mutant 
presenilin variants that bind beta-catenin significantly modify cell growth in vivo (Chevallier et 
al. 2005). Based on all of these lines of independent evidence, we hypothesized that DIF-1 
might function as a novel small molecule with the ability to modulate APP catabolism in 
mammalian cells. Importantly, while there is no cure for Alzheimer's disease, the most 
common form of dementia, and no treatment to reverse or halt its progression, a small number 
of medicines are available that help treat symptoms in some people with the disease. These 
generally fall within the class of drugs known as cholinesterase inhibitors, but unfortunately 
are limited in their efficacy. At least 80 drugs, from vitamin E to Liptor™ to Abeta 
immunotherapies have been or are currently being tested in clinical trials. Unfortunately, the 
large majority of drugs fail or are discontinued from clinical trials, and to discuss the many 
drugs being tested is well beyond the scope of this chapter. However, it should be noted that 
Dictyostelium might also serve as a source of natural molecules with biomedical potential in the 
treatment of neurodegenerative disease. 
3.1.1 DIF-1 reduction of APP secretion Abeta production in cultured mammalian cells 
is cell cycle-dependent 
I will now discuss DIF-1, a unique, small-molecule from Dictyostelium and its ability to 
significantly reduce Abeta production in a large variety of mammalian cells from mouse 
embryonic fibroblasts to neuronally derived mouse N2a and human SH-SY5Y cells (Myre et 
al. 2009). In all cell types tested, DIF-1 inhibited cellular proliferation without inducing any 
detectable cytotoxic effects and simply washing the cells with phosphate buffered saline 
restored their rate of proliferation. Moreover, the cytostatic effect of DIF-1 was coupled with 
an average decrease of 82.41±0.74% in cyclin D1 levels and an increased number of cells in 
G0/G1 (Myre et al. 2009). Since healthy post-mitotic neurons are relatively locked in a 
G0/G1 state to prevent proliferation or migration (Arendt, 2003) and aberrant cyclin 
D1/cdk4 expression has been reported in AD-diseased brain regions suggesting entrance 
into S-phase (Khurana et al. 2006; Yang et al. 2006) one might speculate that as a 
consequence of aberrant cycling, associated with age-dependent, environmentally acquired 
insults, creates a biochemical state that results in increased APP processing. To see if cyclin 
D1 levels were correlated with either an increase or decrease in APP processing we treated 
cells with DIF-1 and monitored the levels of secreted APP and Abeta, and the proteolysis of 
APP into alpha- and beta-C-terminal fragments, respectively (Figure 7a-e).  
www.intechopen.com
 
Neurodegeneration 
 
218 
 
Fig. 7. DIF-1 reduces secretion of APP and inhibits Abeta production. (a) Western blot 
analysis shows CHO cells treated with DIF-1 show reduced levels of secreted APP into the 
media as analyzed using three different anti-APP N-terminus antibodies (shown on right). (b) 
Western blot analysis shows DIF-1 also reduced total secreted Abeta in conditioned media. 
(c) Levels of Abeta40 and Abeta42 were measured by sandwich ELISA. The graph 
represents the percent average reduction of Abeta (±S.D.) (n=3) compared to controls. Black 
bars = non-treated cells, grey bars = vehicle and white bars = DIF-1 treated CHO cells. One 
asterisk represents a P value < 0.003; two asterisks represent a P value < 0.001. (d) Extracts 
from CHO cells that stably overexpress BACE1 were treated with increasing concentrations 
of DIF-1 (0, 1, 5, 10, 20 and 30 μM) (triangle) show reduced proteolysis and CTF levels (e) The 
levels of secreted Abeta40 and Abeta42 is significantly reduced in conditioned media from 
CHO cells that stably overexpress BACE1 as measured by sandwich ELISA. One asterisk 
represents a P value < 0.003, two asterisks represent a P value < 0.001, and three asterisks 
represent a P value < 0.0005. Permission: Myre M.A. et al. (2009). Reduced amyloidogenic 
processing of the amyloid beta-protein precursor by the small-molecule Differentiation 
Inducing Factor-1. Cellular Signalling, 21(4), pp. 567-76. 
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As shown in figure 7, DIF-1, in a dose-dependent manner, decreased the level of secreted 
APP compared to controls, reduced APP maturation and beta-CTF levels and is associated 
with a differential reduction in the levels of Abeta40 (44.2±3.4%) and Abeta42 (66.9±2.6%). 
Taken together, the data suggests that in the presence of DIF-1, APP processing into Abeta 
either occurs less during the G0/G1 phase of the cell cycle or is directly affected by DIF-1. 
Importantly, these results were obtained from CHO cells with increased BACE1 expression 
and suggest that BACE1 activity is most likely not inhibited or targeted by DIF-1. The effect 
of DIF-1 on APP processing is also not a result of a general disruption in metabolic 
processing of type I transmembrane proteins, as when we investigated its effect on a highly 
related protein, APP-like protein 1 (APLP1), DIF-1 did not affect APLP1 maturation or CTF 
production.  
3.1.2 The mechanism by which DIF-1 reduces of Abeta production involves APP 
phosphorylation at Thr668  
Notably, APP that is phosphorylated at residue Thr668 appears to be a preferred substrate 
for amyloidogenic cleavage (Vingtdeux et al. 2005). We next assessed whether DIF-1 alters 
the level of APPT668 phosphorylation and found that in the presence of DIF-1, APP 
phosphorylation at Thr668 is drastically reduced (88.7± 3.16%) (Myre et al. 2009) and implies 
that the mechanism by which DIF-1 reduces amyloidogenic processing of APP is dependent 
upon the phosphor-state of this residue. In order to determine the importance of the Thr668 
residue with respect to the effect of DIF-1 on APP metabolism, we generated constructs that 
result in changes of the Thr688 residue to either Thr688A or Thr688E which would result in 
the production of APP molecules that cannot be phosphorylated at Thr668. Unexpectedly, 
DIF-1 had no affect on the metabolic processing of either APPT668A or APPT668E as 
compared to wild type APP751. The APPT668E and APPT668A mutations abolished the 
effect of DIF-1 on APP maturation, CTF levels and total Abeta production. This result was 
surprising since the T668E mutation was expected to mimic a permanently phosphorylated 
form of APP. We then performed a bioinformatic analysis of the APP C-terminal sequence 
which predicts that mutating residue Thr668 to any other amino acid (with the exception of 
serine) in this region no longer meets the criteria as a potential group IV WW-binding motif 
(Ser/Thr-Pro). This form of WW domain is a small phosphoserine- or phosphothreonine-
binding protein module found in various proteins that participate in cell signaling or 
binding regulation, including physiological substrates of enzymes, in a phosphorylation-
dependent manner (Lu et al. 1999). We suggest that a glutamic acid residue cannot 
compensate for the actual phosphorylation of Thr668 with respect to the mechanism of DIF-
1 action on APP processing. Future work on the mechanism of DIF-1 regarding APP 
processing and phosphorylation of Thr668 will hopefully elucidate how this residue 
functions in a modulatory manner in the production of Abeta. 
The normal function of APP has remained elusive since its' initial discovery in 1987 and 
consequently, knowledge of the biology behind AD pathogenesis remains limited. This 
research is important because it has confirmed the importance of deregulated 
phosphorylation of APP and identification of cell-cycle markers in postmortem AD brains as 
important pathogenic mechanisms. Moreover, DIF-1 represents a novel small-molecule with 
the potential for therapeutic investigation into the pathological mechanisms that result in 
AD with the long-term possibility to serve as a lead molecule in the development of 
structural analogs in the pursuit of AD therapies. Further to this, DIF-1 serves as yet another 
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compound the will help to realize the promise in the area of “chemical genomics.” The goal 
of this application of genomics is to expand the universe of small molecules that can be used 
as probes for understanding biological pathways. While the human genome appears to 
contain more than 20,000 genes, the entire current pharmacopoeia targets only about 500 
genes and their products (Drews, 2000). The use of chemical biological tools provides 
another resource that will compliment existing models and may allow for the discovery of 
alternative pathways that regulate Abeta production. We believe that our findings set the 
stage for the use of DIF-1 as a molecular probe to further elucidate cell cycle-dependent 
signaling mechanisms that regulate amyloidogenic processing of APP in mammalian 
systems and further suggest that Dictyostelium is a potential resource for unique molecules 
with biomedical relevance. 
4. Future value and limitations of Dictyostelium as a biomedical model 
All eukaryotic organisms share a cellular organization made up of functionally distinct, 
membrane-enclosed compartments such as the nucleus, endosome, mitochondria and 
endoplasmic reticulum/Golgi. In addition, similar, if not identical, mechanisms across 
diverse species control the cell cycle and division, the establishment of cell polarity (e.g., 
polarity and motility of chemotaxing Dictyostelium) in unicellular as well as multicellular 
eukaryotes. It is therefore important to not overlook the many basic molecular biological 
processes which are shared by all eukaryotes, of varying complexities, and in doing so 
exploit the strengths of each model system. It is my hope that this review exemplifies how 
the lower organism Dictyostelium fulfills the necessary scientific requirements that qualify its 
future use as an invaluable tool to understand the conserved cellular roles of genes 
implicated in neurodegenerative disorders. I believe most would agree that it is of 
fundamental importance to gain as much understanding about the earliest underlying 
pathogenic processes of any devastating human disease in order to increase drug efficacy 
and/or appropriate therapeutic targeting, but to also work towards a cure. This section will 
outline the cost-effectiveness of Dictyostelium, the rapid nature in which reverse genetics and 
genetic modifier screens can be employed to mine even the most subtle of phenotypes, and 
the recent discoveries of cell-cell signaling molecules that were previously thought to only 
exist in higher metazoan systems. Taken together, the genetic tractability of this model 
organism has the magnificent capacity in certain circumstances to illuminate protein 
function(s) and mechanisms that are conserved in higher organisms by careful, cross-species 
phenotypic analysis and biochemical structure/function studies.  
4.1 Dictyostelium – A valuable model organism for biomedical research 
For any model system to be of practical use, not only should it allow for the study of 
numerous basic and specialized physiological processes, but it must also do so in a cost-
effective fashion. Dictyostelium undeniably offers great economic advantages over other 
eukaryotic systems as cells can grow in simple medium at room temperature effectively 
limiting the need for costly growth incubators. Furthermore, Dictyostelium cells can grow to 
very high cell density (1011 clonal cells) in a few days without the need for highly 
sophisticated equipment. The multicellular development is much shorter compared to 
mammalian systems and can be induced to proceed in a highly synchronous manner 
allowing for the rapid detection of developmental phenotypes. The haploid nature of the 
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genome allows one to create gene deletions at a rate unparalleled in mammalian systems 
including the creation of strains that carry multiple gene deletions. Quite simply when all 
things are considered, the cell culture conditions are simple, inexpensive, less time consuming, 
and not as labor intensive as they are for mammalian cells, thereby making it a highly 
attractive, complementary biological system. As such, Dictyostelium, as a model system, has 
been chosen by the National Institutes of Health as part of its Model Organism Initiative.  
Dictyostelium is a powerful molecular system as it offers most of the numerous molecular 
genetics techniques available for mammalian cells, including gene knock-out, gene knock-in, 
restriction enzyme-mediated mutagenesis (REMI), RNAi, and inducible gene expression, 
allowing a wide range of biological questions to be tested. The haploid nature of the genome 
clearly allows for the unbiased discovery of direct and indirect genetic modifiers of disease 
through comprehensive genetic screens. The successful use of cDNA complementation 
/multi-copy suppression strategies that correct phenotypic defects is well described and can 
be used in combination with the REMI technique to perform saturation screens aimed at 
recovering genetic modifiers (Kuspa & Loomis, 1994; Robinson & Spudich, 2000). REMI 
involves the transformation of cells with a mixture of plasmid DNA linearized with a 
restriction enzyme, along with a restriction enzyme capable of creating compatible cohesive 
ends in the genome (Kuspa, 2006). This powerful screening technique is not available in 
higher organisms, and in addition, makes it possible to carry out genetic selection schemes 
and screens in which greater than a billion progeny can be generated and tested. Genetic 
schemes of this kind are effective at isolating potential second-site intragenic suppressor loci 
as well as saturating for second-site mutations which modify the phenotype of a given 
mutant. Clearly this model system has no equal for establishing the networks of gene action 
involved in basic cell biological processes. However, one limitation of using unicellular 
organisms as models for assessing the function of genes involved in disease is that 
pathologies which affect specific organs cannot be as readily assessed as it might be in the 
relevant organism. This limitation may also apply to genes that are present in unicellular 
organisms but are required in a more stringent manner in specialized tissues, or expressed 
as a variety of different isoforms in specific cell types. Although Dictyostelium develops into 
a bona fide multicellular organism, it does present a limitation in the number of cell types 
that can be analyzed and therefore discoveries made using this organism must be rigorously 
assessed in the relevant mammalian cell type.  
4.1.1 The surprising discovery of neurotransmitter homologues in Dictyostelium 
Of the variety of mechanisms evolved that allow for cell-to-cell communication in animals, 
none maybe more complex than that within the mammalian brain. However, there is evidence 
to suggest that some of these mechanisms were already in use by pre-metazoan cells, prior to 
the development of nervous systems, and surprisingly, there exists a body of evidence for a 
functional role of neurotransmitter receptor homologues in the social amoeba Dictyostelium. 
Unlike the unicellular yeasts, Dictyostelium is not a confined immotile unicellular organism but 
a model system with a short life-cycle that comprises both cellular and multicellular 
developmental stages. Even in its amoeboid stage Dictyostelium can be considered a dynamic 
organism that is capable of carrying out many physiological processes once thought to only 
occur in higher metazoan systems. A prime example of this is the recent findings that the 
family of G-protein coupled receptors (GPCRs) linked to GABAB receptors, that are typically 
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found in the central and peripheral autonomic nervous system that respond to a wide range of 
signals (e.g., main neurotransmitters glutamate, gamma-aminobutyric acid and for Ca2+) were 
considered animal-specific and were not found outside the metazoan branch until the 
Dictyostelium genome was sequenced (Eichinger et al. 2005; Prabhu & Eichinger, 2006). In total, 
17 genes encoding GABAB like receptors were identified based upon homology and are named 
GrlA through GrlR (GABAB or metabotropic glutamate – receptors like proteins) (Prabhu et al. 
2007). Dictyostelium produces GABA in both growing and developing cells (Anjard & Loomis, 
2006). Two genes exist in the Dictyostelium genome that encodes the enzyme glutamate 
decarboxylase which converts glutamate to GABA. Signaling in the central nervous system is 
mediated to a large extent by glutamate and GABA. These intercellular signaling molecules 
and their receptors have been found in C. elegans, Drosophila and all vertebrates but are not 
found in protists or yeasts. Glutamate and GABA activate ionotrophic and metabotropic 
receptors on the surface of neurons to initiate and modulate neurotransmission and also play 
roles in peripheral tissues. The generation of a grlE–null strain by homologous recombination 
found that Dictyostelium cells of this strain do not produce SDF-2, a secreted peptide similar to 
the mammalian neuropeptide diazepam binding inhibitor (DBI), and as a consequence, 
impairs the timing of sporulation in response to GABA (Anjard & Loomis, 2006). This suggests 
that GrlE is the GABA receptor in Dictyostelium and the findings have revealed that GABA 
functions not only as a neurotransmitter but has an early intercellular signaling role setting the 
stage for future studies on the molecular evolution of nervous systems. 
Neurotransmitter homologues in Dictyostelium are not limited to glutamate and GABA 
signaling. Five genes homologous to animal P2X receptors have also been identified in 
Dictyostelium (named p2XA through p2XE) (Fountain et al. 2007; Fountain & Burnstock, 
2009) and allows for the evolutionary study of purinergic receptors. In Dictyostelium, P2XA 
is an exclusively intracellular receptor, which is in contrast to the predominant cell surface 
expression of animal receptors, and localizes to the membrane of the contractile vacuole 
(Fountain et al. 2007). Deletion of the p2XA gene results in an osmoregulatory phenotype, 
where the cell volume decrease in response to hypoosmotic stress is abolished (Fountain et 
al. 2007). Although it is clear that the activity of this receptor is not entirely similar to the 
function of neuronal P2X receptors, these findings do imply that P2XA is absolutely 
required for the function of an intracellular compartment and has lead to the analysis of 
potential roles for P2X receptors in mammalian vacuoles (Qureshi et al. 2007). 
Glutamatergic, GABAergic and purinergic receptors are all present in Dictyostelium which 
represents a fascinating opportunity to garner insight into how these signaling molecules 
have evolved to function in neuronal signaling in animals and additionally, suggests 
neurotransmitters were in operation well before the development of the synapse. 
The fact that Dictyostelium, the ancestor of vertebrate and invertebrate model organisms, 
appears as a highly evolved organism that had already invented complex interacting 
systems to control development, cellular physiology, and cellular behavior has profound 
implications for biomedical genetic research. The central points that I have explored in this 
chapter can be broadly put into two categories: (1) the great advantages of model organisms, 
specifically Dictyostelium, for identifying and understanding genes that are altered in 
heritable human diseases and (2) the functions of many of those genes and the evidence that 
they were present long ago and have remained largely intact in both vertebrate and 
invertebrate lineages during the course of evolution. New perspectives on disease 
www.intechopen.com
 
Dictyostelium discoideum: Novel Insights into the Cellular Biology of Neurological Disorders 
 
223 
pathologies are often a result of data collected from unbiased experimental approaches or 
saturation screens. Often, the identification of novel genetic modifiers then become prime 
targets of investigation in mammalian systems to explore their potential effects as players in 
the pathogenesis of disease and as possible alternative therapeutic targets. The logic behind 
using lower organisms to perform these screens is to partially cripple a process or pathway 
with a mutation which affects one component and then search for alterations in other genes 
encoding component functions in the same system. Importantly, one of the often overlooked 
but added values from studies using simple models is that they have the potential to open 
radically new perspectives in the study of a given pathology. 
5. Conclusion 
Several Dictyostelium genes are homologous or at the very least, retain a significant amount 
of structural conservation to human genes making the organism a useful biomedical model 
system. With the entire genome now sequenced and publicly available in a model organism 
database called dictyBase, these sequences will allow molecular and cellular biologists to 
examine with more clarity the complex multifunctional aspects of gene function. Coupled 
with translational experiments and validation in higher eukaryotes, research that utilizes 
Dictyostelium I believe, will expedite and contribute to our understanding of human 
neurological diseases. Individual cell behavior accounts for the many phases of health and 
pathogenic mechanisms that initiate disease. As described earlier, this has been elegantly 
portrayed in Dictyostelium with respect to the precise production of beta-amyloid from the 
heterologous expression of human APP. Chemotaxis is a critical cellular function with 
implications in immune health and embryogenesis and the discovery that Dictyostelium cells 
deficient for HTT show highly defective chemotactic behavior coupled to 
cytoskeletal/membrane deficits under conditions of low ionic conditions may reveal 
conserved mechanisms for this protein in axon guidance, neuritic extensions and 
embryogenesis. In this chapter I have provided a list of examples where studies in 
Dictyostelium have provided information that support, complement, or enhance the 
understanding of the defects that underlie human neurodegenerative diseases or trafficking 
disorders, or may do so in the future. Future endeavors with this organism that increase the 
amount of translational research conducted in higher organism or neuronal cell models will 
be beneficial for understanding both Dictyostelium cellular physiology and, more 
importantly, the cellular mechanisms of human disease. Indeed, bioinformatic analysis of 
the Dictyostelium genome reveals many homologies with animal genes associated with 
disease, drug targets, and the biosynthesis, storage and reception of neurotransmitters. I 
propose that multiple model systems can and should be employed in the cross-genomic 
analysis of human neurodegenerative disease genes to address multiple basic eukaryotic 
cellular functions (e.g., Dictyostelium), to their assembly into various types of more complex 
molecular pathways (e.g., flies and worms), and then validated and accurately assessed in 
models of human neurodegenerative disease (e.g., mice). 
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